PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Patient Derived Xenograft Model Market, By Model Type (Cell line derived models, Patient derived organoids, Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)), By Implantation Method (Subcutaneous Implantation, Orthopedic Implantation and Others), By Tumor Type (Blood Cancer Models, Solid Tumor Models, Pediatric Tumor Models, Other Rare Tumor Models, Combination PDX Models, Custom PDX Models, Others), By Application (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model and Other Tumor Model), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023
Code : CMI6506
Pages :140
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Patient Derived Xenograft Model Market Drivers:

Increasing Cancer Research: The rising prevalence of cancer globally is driving research initiatives to develop novel anti-cancer drugs and therapies. PDX models are increasingly being used in preclinical and translational oncology research to understand tumor behavior, identify predictive biomarkers, and evaluate drug efficacy. The continuity of molecular and histopathological characteristics from the patient tumor to PDX model enables precise recapitulation of tumor biology and treatment responses. Moreover, the high failure rates of oncology drugs in clinical trials have further augmented the adoption of translational PDX models earlier in drug discovery to improve clinical predictability.
Advancements in PDX Model Generation: Continuous advancements in PDX model generation, such as direct transfer techniques, three-dimensional grafting methods, and co-engraftment of human stromal components, have improved tumor engraftment rates and enabled development of robust PDX platforms. Advancements in imaging, microscopy, and tissue analytic techniques have enhanced characterization and molecular profiling capabilities of PDX models. This has expanded the applications of PDX models in biomarker identification, drug screening, and personalized therapy selection.
Increasing Adoption of Personalized Medicine: The shift towards precision medicine and targeted therapies has amplified the demand for patient-centric disease models. PDX models enable identification of therapies tailored to the molecular profiles of individual patients’ tumors. Pharma companies have integrated PDX models and OMICs technologies into co-clinical trials to adapt treatments in real-time based on PDX-guided drug response data. Several research consortiums have been launched to expand PDX-driven personalized medicine programs.

Patient Derived Xenograft Model Market Opportunities:

Applications in Immunotherapy Testing: The emergence of immune checkpoint inhibitors and CAR T-cell therapies has created lucrative opportunities for PDX models in cancer immunotherapy research. PDX models developed using humanized mice that retain human immune system components are gaining traction in immuno-oncology applications.
Use of PDX Models in Drug Repurposing: The high costs of new oncology drug development have prompted interest in repurposing existing drugs for cancer treatment. PDX models enable cost-effective screening of libraries of approved drugs.
Rising Industry-Academia Collaborations: Increasing collaborations between pharma/biotech firms and academic institutions to accelerate PDX-based oncology research are creating new growth avenues.
Adoption in Clinical Practice: The clinical validity of PDX models has led to their gradual adoption in guiding therapeutic decisions for cancer patients, especially those with rare or aggressive tumors. For instance, the Prospective Validation of Predictive Platinum-based PDX Clinical Trial is an ongoing clinical study testing PDX model-guided therapies in lung cancer patients. The integration of PDX models into standard clinical practice represents an important opportunity area.